Clinical trials · Washington, D.C., DC
Cancer clinical trials in Washington, D.C.
We’re tracking 966 recruiting cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT01441089Recruiting
Donate blood for genetic testing in an NIH research study
This study collects blood from people already in an NIH (National Institutes of Health) clinical research program to run genetic tests. It may help researchers understand cancer and related inherited conditions by studying DNA changes.
Bethesda, MarylandAges 3 years+ - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Bethesda, MarylandAges 18–120 - NCT05104736RecruitingPhase 2
PT-112 for thymus gland tumors after prior chemotherapy
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
Bethesda, MarylandAges 18–120 - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT04185935Recruiting
Genetic study of cancer in patients and their families
This study looks at DNA patterns in families where cancer may run in families, to better understand inherited (passed-down) cancer risk. You may be able to help even if you’re not sure whether your cancer is genetic—your family history and, if needed, medical records or tumor samples can be used.
Bethesda, MarylandAges Any age - NCT05849480RecruitingPhase 1/Phase 2
Study of CD40 treatment with CAPOX and Keytruda for bile duct cancer
This trial studies a new immune “switch” treatment called CDX-1140 combined with standard chemo (CAPOX) and Keytruda, for biliary tract cancer that can’t be cured with surgery or transplant. It’s designed for people whose cancer has progressed after first-line treatment, with the goal of improving cancer control and outcomes.
Bethesda, MarylandAges 18–120 - NCT03206060RecruitingPhase 2
Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Bethesda, MarylandAges 18–100 - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Bethesda, MarylandAges 18 years+ - NCT00027274Recruiting
Cancer risk in inherited bone marrow failure syndromes
This study looks at why people with inherited bone marrow failure syndromes (rare genetic conditions affecting blood cell production) have higher cancer risk. Researchers want to understand the genetic and medical factors that increase cancer likelihood, which could help doctors monitor and protect affected patients and their families.
Bethesda, MarylandAges 1 day–100 years - NCT05600933Enrolling by invitation
Providing tumor samples to find new treatment targets
This study collects tumor tissue and related blood tests from people who already need a biopsy or surgery as part of their usual care. Researchers use the samples to learn what drives the tumor and how the tumor environment may affect treatment, which could help develop future therapies.
Bethesda, MarylandAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Bethesda, MarylandAges 18 years+ - NCT05588128Recruiting
Scan study for prostate cancer after PSA comes back
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
Bethesda, MarylandAges 18 years+ - NCT03805919Recruiting
Study for men with high inherited risk of prostate cancer
This study is for men who have a known inherited gene change that raises their prostate cancer risk. It aims to help prevent or detect prostate cancer earlier, and you may be asked to undergo MRI and other study steps.
Bethesda, MarylandAges 30–75 - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Bethesda, MarylandAges 12 years+ - NCT07374692Recruiting
Study of treatments for advanced brain and spinal cord tumors
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
Bethesda, MarylandAges 15–120 - NCT05027945RecruitingPhase 2
Stem cell transplant for people with VEXAS syndrome
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
Bethesda, MarylandAges 18–75 - NCT00923065Enrolling by invitation
NCI care and data study for patients and donors
This study helps collect information and provide certain clinical care and interventions for people who come to the National Cancer Institute (NCI) Clinical Center (CCR). It may be a fit if you need NCI-level evaluation or support because your condition is complex, or if you’re involved as a cellular therapy donor or certain family members needing genetic testing.
Bethesda, MarylandAges 4 weeks–120 years - NCT04755205Recruiting
Natural history study of olfactory neuroblastoma
This study follows people with olfactory neuroblastoma over time to better understand how the disease behaves and changes. It may help future patients by improving doctors’ knowledge, even if it does not test a new treatment.
Bethesda, MarylandAges 3–120 - NCT05616650RecruitingPhase 2
Targeted radiation for one prostate tumor spot
This Phase 2 study tests a focused radiation approach using stereotactic body radiation therapy (SBRT) for people with one prostate tumor visible on imaging. It aims to treat a single tumor area while limiting treatment to the rest of the prostate.
Bethesda, MarylandAges 18–120
Hear when a new Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting cancer studies listed above.
- National Institutes of Health Clinical Center · 21 studies
- National Cancer Institute (NCI) · 2 studies
- Frederick Oncology Hematology Associates
- National Cancer Institute - Shady Grove
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Suburban Hospital
- Walter Reed National Military Medical Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in District of Columbia.
Common questions
- Are there cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 966 recruiting cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.